June 28, 2017 – In the spring of 2017,  the HRS Subcommittee on Reimbursement and Regulatory Affairs released a statement recommending that private payers provide coverage for subcutaneous implantable cardiac defibrillator (S-ICD) therapy, consistent with FDA labeling.

Topic

  • Coding
  • Reimbursement

Resource Type

  • Guidelines & Protocols